SCHEMBL5136154

SCHEMBL5136154

CCCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCCC)Cc1ccccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.41
ALDH1A1 P00352 4/20 0.39
TSHR P16473 3/20 0.39
KDM4E B2RXH2 3/20 0.39
CYP3A4 P08684 3/20 0.39
HPGD P15428 3/20 0.39
HSD17B10 Q99714 3/20 0.39
PDE4B Q07343 2/20 0.39
CNR2 P34972 1/20 0.39
HDAC1 Q13547 1/20 0.37
TP53 P04637 1/20 0.36
CRHR1 P34998 1/20 0.36
POLB P06746 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134961 0.97 C5AR1 (0.43) C5AR1ALDH1A1TSHRKDM4ECYP3A4
SCHEMBL5069993 0.95 C5AR1 (0.39) C5AR1ALDH1A1TSHRKDM4ECYP3A4
SCHEMBL5135308 0.93 C5AR1 (0.41) C5AR1ALDH1A1TSHRKDM4ECYP3A4
SCHEMBL5281498 0.93 C5AR1 (0.43) C5AR1ALDH1A1TSHRKDM4ECYP3A4
SCHEMBL5136494 0.92 P2RX7 (0.41) C5AR1ALDH1A1TSHRKDM4ECYP3A4
SCHEMBL5134968 0.90 C5AR1 (0.42) C5AR1ALDH1A1TSHRKDM4ECYP3A4
SCHEMBL5136698 0.90 ALDH1A1 (0.39) C5AR1ALDH1A1TSHRKDM4ECYP3A4
SCHEMBL5135633 0.90 C5AR1 (0.42) C5AR1ALDH1A1TSHRKDM4ECYP3A4
SCHEMBL5071843 0.90 C5AR1 (0.44) C5AR1ALDH1A1TSHRKDM4ECYP3A4
SCHEMBL5138004 0.89 P2RX7 (0.43) C5AR1ALDH1A1TSHRKDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed